Appeals under way as EC and EMA reject ruling that ousted Rasi
This article was originally published in Scrip
One of last year's most disruptive events for the European Medicines Agency was the loss of its executive director Guido Rasi, who had to step aside in November after the EU's civil service tribunal annulled the procedure that led to his appointment in 2011.
You may also be interested in...
The UK’s departure from the EU imposes a number of requirements on sponsors running EU trials, but it seems that many have still not taken steps to fall into line.
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.
The International Coalition of Medicines Regulatory Authorities have sketched out the criteria that should be met before candidate coronavirus vaccines can proceed into late-stage trials, and agreed on how to design the studies and who should be included.